IP Library › Granted Patent US 12,527,729
Granted Patent B2
US 12,527,729 · App. 18/301,951 · Granted Jan 20, 2026

Minoxidil adjuvant therapies

Inventors: Ofer A. Goren (Irvine, CA); John McCoy (Irvine, CA)
Assignee: Caring Brands, Inc.
A61K8/4953A61K8/14A61K8/35A61K8/355A61K8/498A61K9/127A61K31/122A61K31/353A61K31/506A61P17/14A61Q7/00A61K2800/5922A61K2800/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,729
App. No.
18/301,951
Granted
Jan 20, 2026
Kind
B2
Abstract

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH.

Claims (24)

1 . A composition for treating hair loss, improving hair growth, accelerating hair growth, increasing the sulfonating capacity of a hair follicle cell and/or keratinocyte cell, inducing sulfotransferase in a hair follicle, inducing expression of sulfotransferase, increasing hair thickness and/or diameter, increasing hair growth rate, increasing hair density, accelerating hair growth, treating for alopecia, upregulating sulfotransferase, converting non-responders to minoxidil responders, and/or improving minoxidil response, the composition comprising:

an agent configured to induce expression of sulfotransferase in skin of a person exhibiting the effects of hair loss, wherein the agent is or includes an alkalinizing agent configured to raise intracellular pH of cells in an outer root sheath of a hair follicle;

wherein the agent configured to induce expression of sulfotransferase in skin of a person exhibiting the effects of hair loss is not a salt of minoxidil; and

wherein the agent configured to induce expression of sulfotransferase in skin of a person exhibiting the effects of hair loss is not a bicarbonate; and

wherein the composition does not contain Minoxidil.

2 . The composition of claim 1 , further comprising a penetration enhancer.

3 . The composition of claim 1 , wherein the alkalinizing agent is placed in a liposome containing lecithin.

4 . The composition of claim 1 , wherein the composition is configured to be administered by applying the composition at a predetermined frequency, administering the composition orally, injecting the composition, or providing the composition as an implant.

5 . The composition of claim 1 , further comprising a carrier, wherein the composition is formulated as any one or combination of a shampoo, a foam, ointment, spray, solution, gel, slow release capsule, oral tablet, dry shampoo, hair styling product or exfoliating agent.

6 . The composition of claim 1 , wherein the composition is formulated as a cosmetic product.

7 . The composition of claim 1 , wherein the composition is formulated as any one or combination of a time release vehicle, a cream, a solution, a lotion, a serum, an ointment, a spray, an aerosol medium, a capsule, a shampoo, a gel, a foam, a cosmetic, a hair conditioner, a hair care product, a hair mask, a deodorant, an antiperspirant, a moisturizer, or a shaving cream or gel.

8 . A kit for treating hair loss, improving hair growth, accelerating hair growth, increasing the sulfonating capacity of a hair follicle cell and/or keratinocyte cell, inducing sulfotransferase in a hair follicle, inducing expression of sulfotransferase, increasing hair thickness and/or diameter, increasing hair growth rate, increasing hair density, accelerating hair growth, treating for alopecia, upregulating sulfotransferase, converting non-responders to minoxidil responders, and/or improving minoxidil response, the kit comprising the composition of claim 1 and a dispenser, implant, or pill.

9 . The kit of claim 8 , wherein the composition is formulated as any one or combination of a time release vehicle, a cream, a solution, a lotion, a serum, an ointment, a spray, an aerosol medium, a capsule, a shampoo, a gel, a foam, a cosmetic, a hair conditioner, a hair care product, a hair mask, a deodorant, an antiperspirant, a moisturizer, or a shaving cream or gel.

10 . A method for treating hair loss, improving hair growth, accelerating hair growth, increasing the sulfonating capacity of a hair follicle cell and/or keratinocyte cell, inducing sulfotransferase in a hair follicle, inducing expression of sulfotransferase, increasing hair thickness and/or diameter, increasing hair growth rate, increasing hair density, accelerating hair growth, treating for alopecia, upregulating sulfotransferase, converting non-responders to minoxidil responders, and/or improving minoxidil response, the method comprising:

applying an effective amount of a composition including an agent configured to induce expression of sulfotransferase in skin of a person, and applying topical, oral, or both topical and minoxidil;

wherein the agent includes an alkalinizing agent;

wherein the agent configured to induce expression of sulfotransferase in skin of a person exhibiting the effects of hair loss is not a salt of minoxidil; and

wherein the agent configured to induce expression of sulfotransferase in skin of a person exhibiting the effects of hair loss is not a bicarbonate; and

wherein the composition does not contain Minoxidil.

11 . The method of claim 10 , wherein treating for alopecia includes treating for alopecia areata, treating for chemotherapy induced alopecia, treating female and/or male pattern hair loss, and/or treating androgenetic alopecia.

12 . The composition of claim 1 , wherein treating for alopecia includes treating for alopecia areata, treating for chemotherapy induced alopecia, treating female and/or male pattern hair loss, and/or treating androgenetic alopecia.

13 . The composition of claim 2 , wherein the alkalinizing agent is configured to raise intracellular pH of cells in an outer root sheath of a hair follicle to from 7.4-11.0.

14 . The composition of claim 13 , wherein the alkalinizing agent is a buffer.

15 . The composition of claim 13 , wherein the penetration enhancer is selected from alcohols, glycols, fatty acids, fatty esters, fatty ethers, cyclodextrines, surfactants, dimethylaminopropionic acid derivatives, terpenes, sulfoxides, cyclic ethers, amides, amines, sulphoxides, azones, pyrrolidones alkanols, glycols, oxazolidinones, urea, 2-(1-nonyl)-1,3-dioxolane, terpenes, liposomes, phospholipids, cyclopentadecalactone, pentadecalactone, SNAC, salcaprozate sodium N-[8-(2-hydroxybenzoyl) amino]caprylate, CNAC, 5-CNAC, 8-(N-2-hydroxy-5-chloro-benzyl)-amino-caprylic acid, sodium caprate, glyceryl triglyceride, and peptides.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2024
From: APPLIED BIOLOGY, INC.
To: JUPITER WELLNESS, INC.
Reel/Frame 066548/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2024
From: GOREN, OFER A.; MCCOY, JOHN
To: APPLIED BIOLOGY, INC.
Reel/Frame 066666/0970 →
Continuity (8)
Continuation 16747685 · Jan 21, 2020
Continuation In Part 16593577 · Oct 4, 2019
Provisional Application 62895627 · Sep 4, 2019
Provisional Application 62849598 · May 17, 2019
Provisional Application 62800065 · Feb 1, 2019
Provisional Application 62756293 · Nov 6, 2018
Provisional Application 62741990 · Oct 5, 2018
Related Publication 20230404886A1 · Dec 21, 2023
References Cited (60)
US 3317384A · Underwood · 1967 [cited by applicant]
US 5148822A · Akhtar · 1992 [cited by applicant]
US 5360804A · Gaetani et al. · 1994 [cited by applicant]
US 5373006A · Grollier · 1994 [cited by applicant]
US 5384126A · Bonte et al. · 1995 [cited by applicant]
US 6010690A · Varco · 2000 [cited by applicant]
US 8691518B2 · Tam et al. · 2014 [cited by applicant]
US 11628132B2 · Goren et al. · 2023 [cited by applicant]
US 11766392B2 · Goren et al. · 2023 [cited by applicant]
US 20030007941A1 · Cornelius et al. · 2003 [cited by applicant]
US 20030215409A1 · Quinn · 2003 [cited by examiner]
US 20090214628A1 · de Rijk · 2009 [cited by applicant]
US 20160220465A1 · Goren et al. · 2016 [cited by applicant]
US 20180050858A1 · May et al. · 2018 [cited by applicant]
US 20200214958A1 · Goren et al. · 2020 [cited by applicant]
US 20210059920A1 · Goren et al. · 2021 [cited by applicant]
US 20220296486A1 · Goren et al. · 2022 [cited by applicant]
US 20240009101A1 · Goren et al. · 2024 [cited by applicant]
KR 20090088013A · 2009 [cited by applicant]
WO 2003055457A1 · 2003 [cited by applicant]
WO 2014056070 · 2014 [cited by applicant]
WO 2023239972A1 · 2023 [cited by applicant]
CN110548044A Machine Translation (Year: 2019). [cited by examiner]
JP2015187094A Machine Translation (Year: 2015). [cited by examiner]
Admin, title: pH of the skin and Body—The Science Responsible for Life; published Nov. 20, 2017; downloaded from https://www.stlouishair.com/ph-of-the-skin-and-body-the-science-responsible-for-life/ (year:2017). [cited by applicant]
Bryant et al., “Here's What You Need to Know About the Latest Korean Beauty Obsession,” [cited by applicant]
Dooley, T.P., “Localization of Minoxidil Sulfotransferase in Rat Liver and the Outer Root Sheath of Anagen Pelage and Vibrissa Follicles,” The Journal of Investigative Dermatology, p. 65-70, (1991). [cited by applicant]
Martins Gomes et al., “The Risk of Leprosy in Patients Using Immunobiologics and Conventional Immunosuppressants for the Treatment of Dermatological and Rheumatological Diseases: A Cohort Study,” Journal of the European… [cited by applicant]
Matos et al., “Chitosan Nanoparticles for Targeting and Sustaining Minoxidil Sulphate Delivery to Hair Follicles,” Int J Biol Macromol., vol. 75, p. 225-229, (2015); Abstract Only. [cited by applicant]
Ramos et al., “Novel Topical Booster Enhances Follicular Sulfotransferase Activity in Patients with Androgenetic Alopecia: A New Strategy to Improve Minoxidil Response,” Journal of the European Academy of Dermatology an… [cited by applicant]
Santos et al., “Topical Minoxidil-Loaded Nanotechnology Strategies for Alopecia,” Cosmetics, vol. 7, No. 21, 25 pages, (2020). [cited by applicant]
Bian, H. et al., “Induction of human sulotransferase 1A3 (SULT1A3) by glucocorticoids,” Life Sciences, vol. 81, No. 25-26, pp. 1659-1667, (2007). [cited by applicant]
Anonymous, “pH of the Skin and Body—The Science Responsible for Life,” StLouisHair.com, 14 pages, (2017); retrieved on Sep. 17, 2020 from www.stlouishair.com/ph-of-the-skin-and-body-the-science-responsible-for-life/. [cited by applicant]
Alnouti et al., “Regulation of Sulfotransferase Enzymes by Prototypical Microsomal Enzyme Inducers in Mice,” J Pharmacol Exp Ther., vol. 324, No. 2, p. 612-621, (2008); Abstract Only. [cited by applicant]
Bryant, T., “Here's What You Need to Know About the Latest Korean Beauty Obsession,” Scalp PH Facts—PH Balanced Shampoo Products, 4 pages, (2016). [cited by applicant]
Buhl et al., “Minoxidil Sulfate is the Active Metabolite that Stimulates Hair Follicles,” Journal of Investigative Dermatology, vol. 95, No. 5, p. 553-557, (1990). [cited by applicant]
Bunchorntavakul et al., “Acetaminophen (APAP or N-Acetyl-p-Aminophenol) and Acute Liver Failure,” Clin Liver Dis., vol. 22, No. 2, p. 325-346, (2018); Abstract Only. [cited by applicant]
Charruyer et al., “Influence of pH on Skin Stem Cells and Their Differentiation,” Curr Probl Dermatol., vol. 54, p. 71-78, (2018); Abstract Only. [cited by applicant]
Croom, E., “Metabolism of Xenobiotics of Human Environments,” Prog Mol Biol Transl Sci., vol. 112, p. 31-88, (2012); Abstract Only. [cited by applicant]
Dooley et al., “Localization of Minoxidil Sulfotransferase in Rat Liver and the Outer Root Sheath of Anagen Pelage and Vibrissa Follicles,” The Journal of Investigative Dermatology, vol. 96, No. 1, p. 65-70, (1991). [cited by applicant]
Gonzalez et al., “Regulation of Cytochrome P450 Genes: Molecular Mechanisms,” Pharmacogenetics, vol. 3, No. 1, p. 51-57, (1993); Abstract Only. [cited by applicant]
Goren et al., “Novel Enzymatic Assay Predicts Minoxidil Response in the Treatment of Androgenetic Alopecia,” Dermatologic Therapy, vol. 27, No. 3, p. 171-173, (2014). [cited by applicant]
Goren et al., “Clinical Utility and Validity of Minoxidil Response Testing in Androgenetic Alopecia,” Dermatologic Therapy, vol. 28, No. 1, 4 pages, (2014). [cited by applicant]
Handschin et al., “Induction of Drug Metabolism: The Role of Nuclear Receptors,” Pharmacol Rev., vol. 55, No. 4, p. 649-673, (2003); Abstract Only. [cited by applicant]
Honkakoski et al., “Drug-activated Nuclear Receptors CAR and PXR,” Annals of Medicine, vol. 35, pp. 172-182, (2003). [cited by applicant]
Jakoby et al., “The Enzymes of Detoxication,” The Journal of Biological Chemistry, vol. 265, No. 34, p. 20715-20718, (1990). [cited by applicant]
Jancova et al., “Phase II Drug Metabolizing Enzymes,” Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub., vol. 154, No. 2, p. 103-116, (2010); Abstract Only. [cited by applicant]
Johnson et al., “Minoxidil Sulfotransferase, A Marker of Human Keratinocyte Differentiation,” Journal of Investigative Dermatology, vol. 98, No. 5, p. 730-733, (1992). [cited by applicant]
Maglich et al., “Nuclear Pregnane X Receptor and Constitutive Androstane Receptor Regulate Overlapping But Distinct Sets of Genes Involved in Xenobiotic Detoxification,” Mol Pharmacol., vol. 62, No. 3, p. 638-646, (2002… [cited by applicant]
Nimmagadda et al., “Cytosolic Sulfotransferases,” Indian J Exp Biol., vol. 44, No. 3, p. 171-182, (2006); Abstract Only. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/593,577 dated Sep. 23, 2020. [cited by applicant]
Olsen et al., “A Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men,” Journal of … [cited by applicant]
Owen et al., “Intestinal Detoxification Limits the Activation of Hepatic Pregnane X Receptor by Lithocholic Acid,” Drug Metab Dispos., vol. 38, No. 1, p. 143-149, (2010). [cited by applicant]
Parkinson et al., “Chapter 6: Biotransformation of Xenobiotics, Casarett and Doull's Toxicology: The Basic Science of Poisons”, McGraw-Hill Education, New York, NY, USA, 189 pages, (2013). [cited by applicant]
Runge-Morris et al., “Regulation of Sulfotransferases by Xenobiotic Receptors,” Curr Drug Metab., vol. 6, No. 4, p. 299-307, (2005); Abstract Only. [cited by applicant]
Runge-Morris et al., “Regulation of the Cytosolic Sulfotransferases by Nuclear Receptors,” Drug Metab Rev., vol. 45, No. 1, 31 pages, (2013). [cited by applicant]
Tiwari et al., “Nanocarriers for Skin Applications: Where Do We Stand?” Angew Chem Int Ed., vol. 61, No. e202107960, 26 pages, (2022). [cited by applicant]
Trommer et al., “Overcoming the Stratum Corneum: The Modulation of Skin Penetration. A Review,” Skin Pharmacol Physiol., vol. 19, No. 2, p. 106-121, (2006); Abstract Only. [cited by applicant]
Xu et al., “Induction of Phase I, II and III Drug Metabolism/Transport by Xenobiotics,” Arch Pharm Res., vol. 28, No. 3, p. 249-268, (2005); Abstract Only. [cited by applicant]
Prosecution of U.S. Appl. No. 16/747,685, filed Jan. 21, 2021. [cited by applicant]